Opexa therapeutics announces phase II clinical trial results of its T cell vaccine tovaxin
Opexa therapeutics announced results of its phase II clinical trial evaluating the effectiveness of its T cell vaccine, tovaxin, in people with relapsing-remitting MS.
To read more, as reported by the UK MS Society, click here.
